On 12 October 2017, orphan designation (EU/3/17/1945) was granted by the European Commission to Medical Need Europe AB, Sweden, for tiratricol for the treatment of Allan-Herndon-Dudley syndrome.
Treatment of Allan-Herndon-Dudley syndrome
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The sponsor’s address was updated in April 2022.
The sponsorship was transferred to MN Development AB, Sweden, in May 2018.
In November 2018, MN Development AB changed name to Rare Thyroid Therapeutics.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: